Clinical Trial Update: A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 trial update on YTS109 cell therapy for relapsed/refractory autoimmune diseases, currently recruiting across multiple indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Antiphospholipid Syndrome
• Inflammatory Myopathy
• Lupus Nephritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• YTS109 cells

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Status: RECRUITING